Vericel Files 8-K on Operations & Financial Condition

Ticker: VCEL · Form: 8-K · Filed: Jan 9, 2024 · CIK: 887359

Complexity: simple

Sentiment: neutral

Topics: corporate-update, regulatory-filing, compliance

TL;DR

**Vericel filed a standard 8-K, confirming its NASDAQ listing and non-emerging growth company status.**

AI Summary

Vericel Corporation filed an 8-K on January 9, 2024, to report on its financial condition and operations. This filing indicates that the company is not an emerging growth company and its Common Stock, with no par value, is registered on NASDAQ under the trading symbol VCEL. This matters to investors because it confirms Vericel's status as an established public company, subject to full SEC reporting requirements, which can impact investor confidence and regulatory scrutiny.

Why It Matters

This filing provides a routine update on Vericel's corporate status and confirms its listing on NASDAQ, which is important for transparency and market access for investors.

Risk Assessment

Risk Level: low — This 8-K is a routine filing with no new material financial information or significant events that would introduce new risks.

Analyst Insight

A smart investor would note this as a routine compliance filing, confirming Vericel's established public company status, but would look for more substantive filings (like 10-K or 10-Q) for detailed financial performance and future outlook.

Key Players & Entities

FAQ

What is the purpose of Vericel Corporation's 8-K filing dated January 9, 2024?

The 8-K filing by Vericel Corporation on January 9, 2024, reports on 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure,' along with 'Financial Statements and Exhibits,' as indicated by the ITEM INFORMATION section.

What is Vericel Corporation's trading symbol and on which exchange is its common stock registered?

Vericel Corporation's Common Stock, with no par value, is registered on NASDAQ under the trading symbol VCEL, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.

Is Vericel Corporation considered an 'emerging growth company' according to this filing?

No, the filing explicitly indicates with an unchecked box that Vericel Corporation is not an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933.

What is the business address and phone number of Vericel Corporation as listed in the filing?

Vericel Corporation's business address is 64 Sidney Street, Cambridge, MA 02139, and its telephone number is (617) 588-5555, according to the 'BUSINESS ADDRESS' section.

What was Vericel Corporation's former name and when did the name change occur?

Vericel Corporation's former name was AASTROM BIOSCIENCES INC, and the date of the name change was 19960428, as detailed in the 'FORMER COMPANY' section of the filing.

Filing Stats: 846 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-01-09 16:05:56

Filing Documents

02

Item 2.02. Results of Operations and Financial Condition. In connection with its participation in the 42 nd Annual J.P. Morgan Healthcare Conference, on January 9, 2024, Vericel Corporation (the "Company") issued a press release and updated its corporate presentation, both of which include estimates of operating and financial results as of and for the year ended December 31, 2023. The Company's corporate presentation includes additional updates regarding its business. Because the Company's financial statements for the year ended December 31, 2023, have not been finalized or audited, these preliminary statements regarding the Company's operating and financial results as of and for the year ended December 31, 2023, are subject to change and the Company's actual results as of the end of this period may differ materially from this preliminary estimate. Accordingly, stockholders should not place undue reliance on this preliminary estimate. A copy of the Company's January 9, 2024, press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report").

01

Item 7.01. Regulation FD Disclosure. The information set forth in Item 2.02 of this Report is incorporated into this Item 7.01 by reference. The Company will participate in the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, which is being held on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time, and has updated the corporate presentation that the Company intends to use at the conference. The Company may use this updated corporate presentation in meetings with investors from time to time as well. The Company's updated corporate presentation includes disclosure regarding the Company's estimated, preliminary and unaudited full-year revenue for fiscal year 2023, its estimated cash and investments balance as of December 31, 2023, and additional financial and business updates. A copy of the Company's updated corporate presentation is attached hereto as Exhibit 99.2 and is hereby incorporated by reference. In accordance with General Instructions B.2 and B.6 of Form 8-K, the information included in Item 2.02 and Item 7.01 of this Report shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated January 9, 2024, titled "Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results" 99.2 Vericel Corporation Presentation, dated January 9, 2024 104 * Cover Page Interactive Data File (embedded within the Inline XBRL) * Furnished herewith EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated January 9, 2024, titled "Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results" 99.2 Vericel Corporation Presentation, dated January 9, 2024 104 * Cover Page Interactive Data File (embedded within the Inline XBRL) * Furnished herewith.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 , the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vericel Corporation Date: January 9, 2024 By: /s/ Sean C. Flynn Name: Sean C. Flynn Title: Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing